Latest Amgen Stories
CHICAGO, June 5, 2012 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMGN, UAL, DHI, CAKE, and MDC. To see what our analysts have discovered about these stocks read the InvestorsObserver's PriceWatch Alerts at http://www.investorsobserver.com/pr/6420122 (Note: You may have to copy this link into your browser then press the [ENTER] key.) Today's PriceWatch Alerts cover the following stocks: Amgen (Nasdaq: AMGN), United Continental (NYSE: UAL), D.R. Horton...
2012 report from Amgen Canada and Let's Talk Science - Spotlight on Science Learning: A benchmark of Canadian talent MISSISSAUGA, ON, June 5, 2012 /CNW/ - A report released today by Amgen Canada and Let's Talk Science reveals that creating a large pool of science-based talent is crucial to keeping Canada competitive and Canadians employed. The report reveals that while Canadian students perform well in national and international tests, there is a huge drop-off in the uptake of...
POINT RICHMOND, Calif., June 4, 2012 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, announced today that John A. Kollins will join the Company, effective June 1, 2012, and serve as Senior Vice President and Chief Business Officer. In this new position, Mr. Kollins will have primary...
SEATTLE, May 30, 2012 /PRNewswire/ -- Aequus BioPharma, Inc. ("Aequus"), a majority owned subsidiary of Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC), announced today that its GlycoPolymer technology proof of concept studies, featuring recent data with their AQB-101 drug candidate, was selected for an oral presentation at the 9th International Symposium for Polymer Therapeutics meeting. The meeting will be held on May 28-30, 2012, at the Centro de Investigacion Principe...
THOUSAND OAKS, Calif., May 23, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced voting results from the Company's Annual Meeting of Stockholders, held at the Four Seasons Hotel, Westlake Village, Calif. Approximately 87 percent of outstanding shares were represented at the meeting. The director nominees David Baltimore, Robert A. Bradway, Frank J. Biondi, Jr., Vance D. Coffman, Francois de Carbonnel, Rebecca M. Henderson, Frank C. Herringer, Gilbert S. Omenn, Judith C....
In the news release, Amgen's BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, issued 16-May-2012 by Amgen over PR Newswire, we are advised by the company that the third paragraph now includes additional safety information. The complete, corrected release follows: Amgen's BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate Of Complete Response In Adult Patients With Relapsed Or...
THOUSAND OAKS, Calif., May 16, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced updated results from a Phase 2 study that showed treatment with blinatumomab (AMG 103) helped achieve a high-rate of complete response (CR) in 72 percent of adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL) treated in the study. Blinatumomab is the first of a new class of agents called bi-specific T cell engagers (BiTE®) antibodies, designed to harness...
THOUSAND OAKS, Calif., May 16, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) announced today results from an exploratory biomarker analysis evaluating MET expression as a predictor of clinical response to rilotumumab (AMG 102). This analysis, conducted on a previously reported Phase 2 study of rilotumumab in patients with locally advanced or metastatic gastric or gastroesophageal cancer, showed that treatment with rilotumumab in combination with chemotherapy improved median overall...
THOUSAND OAKS, Calif., May 11, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced today that Joseph P. Miletich, M.D., Ph.D., senior vice president of Research and Development at Amgen will testify at the United States (U.S.) Food and Drug Administration (FDA) stakeholder hearing on biosimilars. Miletich will urge members of the FDA panel charged with implementing a pathway for biosimilars to establish approval standards that advance patient safety and promote confidence in...
WASHINGTON and THOUSAND OAKS, Calif., May 9, 2012 /PRNewswire/ -- The Cancer Support Community (CSC) and the Amgen Foundation, today announced the launch of Open to Options(TM), a program designed to bridge the communications gap between physicians and patients and inspire patient confidence in making treatment decisions. Following a successful pilot funded by the Centers for Disease Control (CDC), the Open to Options program is ready to provide professional counselors who help...
